Experiment 372446

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEchinacea angustifolia (ASTERACEAE)
CitationSEE,D: BERMAN,S: JUSTIS,J: BROUMAND,N: CHOU,S: CHANG,J: TILLES,J:. (1998). A PHASE I STUDY ON THE SAFETY OF ECHINACEA ANGUSTIFOLIA AND ITS EFFECT ON VIRAL LOAD IN HIV INFECTED INDIVIDUALS.. 1(1)
Amount utilized
Compound isolated
DiseaseA PHASE I TRIAL OF EA IN HIV(+)-INDIVIDUALS WAS CONDUCTED. FOURTEEN PTS WITH CD4 COUNTS RANGING FROM 6 TO 600/MM3 (MEAN 269) AND VIRAL LOADS (LOG10) RANGING FROM <2.3 TO 5.4 (MEAN 4.68) WERE ENROLLED AND THE 14/15 SUBJECTS WHO COMPLETED THE STUDY INCLUDED THE ANALYSES. EACH HAD BEEN ON A STABLE ANTIRETROVIRAL REGIMEN OR NO ANTI-RETROVIRALS FROM AT LEAST THE PREVIOUS 12 WEEKS. EACH RECEIVED A 12-WEEK COURSE OF EA AT 1000 MG TID. HIV VIRAL LOADS, CD4 COUNTS, NATURAL KILLER (NK) CELL KILLING ACTIVITY AGAINST K562 TARGET CELLS, CLINICAL ASSESSMENT, AND LAB MONITORING FOR TOXICITY WERE DONE EVERY TWO WEEKS. THERE WERE NO CLINICAL OR LABORATORY TOXICITIES NOTED DURING THE STUDY. AT 12 WEEKS THERE WAS NO SIGNIFICANT DIFFERENCE IN MEAN CD4 COUNT COMPARED TO BASELINE, HOWEVER, THERE WAS AN OVERALL 0.32 LOG 10 REDUCTION IN VIRAL LOAD (MEAN 4.36, P<.05). EA DID NOT DEMOSTRATE ANY DIRECT ANTI-HIV KILLING ACTIVITY IN VITRO AND THERE WAS NO CHANGE IN NK ACTIIVITY. THUS, EA WAS SAFE AND ASSOCIATED WITH A SIGNIFICANT REDUCTION IN VIRAL LOAD IN HIV (+) INDIVIDUALS IN THIS PILOT STUDY.
Dose amount3.0 GM
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Per unitDAY
Dose expressionDOSE
ExtractPLANT
GenderGIVEN TO BOTH SEXES